BioPharmSignal logoBioPharmSignal

Biotech News

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics (BRNS)Barinthus BiotherapeuticsEarnings

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closing Multiple ascending

Related news

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

View all latest news

Barinthus Biotherapeutics

Immune-Tolerance Therapeutics Barinthus Biotherapeutics develops immunotherapies intended to retrain the immune system in autoimmune and chronic infectious diseases. Its current internal focus is immune tolerance rather than broad immune stimulation. SNAP-TI Platform The SNAP-Tolerance Immunotherapy platform is designed to deliver...

Recent company news

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-03-13 12:00 EST

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-12-10 13:00 EST

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

BRNSBarinthus Biotherapeutics2025-11-07 12:30 EST

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Stock data

Close
0.57 USD
Market cap
26.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States